• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives
Chin Med J (Engl). 2023 Feb 21. doi: 10.1097/CM9.0000000000002057. Online ahead of print.ABSTRACTThe clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and all-cause mortality benefit of PCSK9i remains inconclusive, current cholesterol management guidelines have been modified toward more aggressive goals for lowering low-density lipoprotein cholesterol (LDL-C). Consequently, the emerging ...
Source: Chinese Medical Journal - February 22, 2023 Category: General Medicine Authors: Xin Zhou Ziping Li Hangkuan Liu Yongle Li Dong Zhao Qing Yang Source Type: research

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
Conclusion: Diffuse atherosclerosis and coronary calcinosis are associated with elevated Lp(a) levels, independent of other risk factors. The risk of MACE in the first year after surgery is significantly higher in patients with diffuse atherosclerosis and coronary calcinosis, which should be considered when prescribing postoperative treatment for such patients.PMID:36359368 | DOI:10.3390/biomedicines10112848
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Larisa N Ilina Olga I Afanasieva Andrey A Shiryaev Elina E Vlasova Said K Kurbanov Marina I Afanasieva Marat V Ezhov Vladislav P Vasiliev Damir M Galyautdinov Sergey N Pokrovsky Renat S Akchurin Source Type: research

Paradoxical Long-Term Impact Between Serum Apolipoprotein E and High-Density Lipoprotein Cholesterol in Patients Undergoing Percutaneous Coronary Intervention
CONCLUSIONS: Serum ApoE levels may have a paradoxical impact on the future cardiovascular risk depending on the HDL-C status in patients with CAD.PMID:35934781 | DOI:10.5551/jat.63535
Source: Journal of Atherosclerosis and Thrombosis - August 7, 2022 Category: Cardiology Authors: Tatsuya Fukase Tomotaka Dohi Ryota Nishio Mitsuhiro Takeuchi Norihito Takahashi Yuichi Chikata Hirohisa Endo Shinichiro Doi Hiroki Nishiyama Iwao Okai Hiroshi Iwata Shinya Okazaki Katsumi Miyauchi Hiroyuki Daida Tohru Minamino Source Type: research

Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11